Affymax (AFFY) "Significantly Undervalued"; Buy on Weakness -Baird
More News related to AFFY
- Affymax to Present at RBC Capital Markets Healthcare Conference
- Affymax (AFFY) Announces Data Monitoring Committee Completes Review of Phase 3 Hematide Program; Trials Support Continuation of Studies
- Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
- Affymax, Inc. (AFFY) Executive Officer to Ring the NASDAQ Stock Market Closing Bell
- Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)
Robert W. Baird reiterates its Outperform rating and $25 price target on Affymax (Nasdaq: AFFY).
The firm said it would be "aggressive buyers of Affymax shares on any potential weakness today as last night's announced discontinuation of Hematide's development in oncology was fully expected. We have not, and do not model, any Hematide oncology revenue."
Today's weakness is the result of an Affymax and Takeda announcement
Baird points to "enrollment completion of the remaining Hematide Phase III trials by YE08" as a potential catalyst which could drive shares higher moving forward.
Notably, shares of Affymax are down nearly 13% from yesterday's close, most recently trading at $15.30. Based on this price, Baird's $25 price target represents potential upside of 63%..
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.
Related Categories
Analyst CommentsInsiders' Blog
Stocks Mentioned
+0.31Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
